The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of ethnicity and immune-related adverse events (IRAE) on outcomes for non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors.
 
Karen Resnick
No Relationships to Disclose
 
Peter Zang
No Relationships to Disclose
 
Travis Larsen
No Relationships to Disclose
 
Shirley Ye
No Relationships to Disclose
 
April Choi
No Relationships to Disclose
 
Xiao Yu
Stock and Other Ownership Interests - Neoleukin Therapeutics
Patents, Royalties, Other Intellectual Property - Neoleukin Therapeutics
 
Kevin Brady
No Relationships to Disclose
 
Trevor E Angell
No Relationships to Disclose
 
Jacob Stephen Thomas
No Relationships to Disclose
 
Jorge J. Nieva
Stock and Other Ownership Interests - Cansera; Epic Sciences; Indee P/L; Quantgene
Consulting or Advisory Role - AstraZeneca; Naveris
Research Funding - Genentech (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters
 
Gino Kim In
Honoraria - Array BioPharma/Pfizer; Bristol-Myers Squibb; regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Novartis; Sanofi
Speakers' Bureau - Merck; Regeneron; Rockpointe CME; Targeted Oncology
Research Funding - Checkmate Pharmaceuticals (Inst); Idera (Inst); Instil Bio (Inst); Regeneron (Inst); Replimune (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Regeneron